DICE Therapeutics
Vanessa Clark has a diverse work experience spanning over several companies and roles. Vanessa is currently serving as the Director of Nonclinical Operations at DICE Therapeutics since April 2022. Prior to this, Vanessa worked at Genentech from 2014 to 2022, holding positions such as Senior Scientific Manager, Scientific Manager, and Study Operations Manager in the Nonclinical Study Operations and Safety Assessment department. Starting in 2008, they worked at SRI International as a Senior Project Manager and later as a Project Manager and Associate Project Manager in the Biosciences Division. Vanessa also has experience in the field of Pharmacology, having worked at FibroGen as a Senior Research Associate and Research Associate II, and at Renovis as a Research Associate II, Research Associate I, and Lead Laboratory Technician. Vanessa began their career as a Laboratory Assistant at the UCSB Neuroscience Research Institute in 2000.
Vanessa Clark, BS, PMP, completed their Bachelor of Science (BS) in Zoology from UC Santa Barbara in 2002. Vanessa then pursued further education at the University of California, Berkeley (Extension) from 2007 to 2009, where they obtained a Certificate with Distinction in Project Management. In addition to their degrees, Vanessa also holds additional certifications. In 2005, they obtained the Assistant Laboratory Animal Technician (ALAT) certification from the American Association for Laboratory Animal Science (AALAS). Furthermore, in August 2016, they obtained the Project Management Professional (PMP)® certification from the Project Management Institute.
This person is not in the org chart
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.